Evidence map›Paper›PMID 38677983›Full record

ArticleJapanese journal of clinical oncology2024

Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.

Masafumi Ikeda, Susumu Hijioka, Tetsuhide Ito, Shigemi Matsumoto, Yoshitaka Honma, Makoto Ueno, Naohiro Okano, Taku Aoki, Junji Furuse

Open access · hybridAbstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID 0000-0002-4050-2086
Susumu HijiokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-0394-6876
Tetsuhide ItoDepartment of Gastroenterology and Hepatology, International University of Health and Welfare Graduate School of Medicine, Neuroendocrine Tumor Center, Fukuoka Sanno Hospital, Fukuoka, Japan.
Shigemi MatsumotoDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.ORCID 0000-0002-4098-5217
Taku AokiDepartment of Hepato-Biliary-Pancreatic Surgery, Dokkyo Medical University, Tochigi, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Kanagawa Prefectural Hospital Organization · JPDokkyo Medical University · JPFukuoka International University · JPJapanese Society of Medical Oncology · JPKyorin University · JPKyoto University Hospital · JPNational Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSomatostatin analogs, molecular-targeted agents and cytotoxic anticancer agents are available as therapeutic agents for the systemic treatment of pancreatic neuroendocrine tumors, and we have developed a first-line treatment selection MAP to enable selection of the optimal treatment strategy for pancreatic neuroendocrine tumors. The purpose of this study was to validate the usefulness of the treatment selection MAP.

methodsPatients who had received systemic therapy for a pancreatic neuroendocrine tumor between January 2017 and December 2020 were compared according to whether they had been treated as recommended by the MAP (matched patients) or not (unmatched patients) to determine whether better outcomes were achieved by the matched patients. The primary endpoint was progression-free survival of the matched group and unmatched groups in the somatostatin analog, molecular-targeted agent and cytotoxic anticancer agents areas of the MAP.

resultsThere were 41 (55%) MAP-matched patients in all areas among the 74 patients registered at seven hospitals. The MAP-matched rates were 100, 77 and 38% in the somatostatin analog area, molecular-targeted agent area and cytotoxic anticancer agents area, respectively. All of the unmatched patients had been selected for less intensive treatment. The median progression-free survival in the matched group and unmatched group in the molecular-targeted agent area of the MAP were 46.6 and 15.4 months, respectively, and a multivariate analysis identified MAP-matched (hazard ratio 0.18 [95% confidence interval: 0.04-0.87], P = 0.032) as the only significant independent favorable predictive factor.

conclusionThe usefulness of the MAP for treatment selection was validated in the molecular-targeted agent area of the MAP.

Indexed as

Neuroendocrine TumorsPancreatic NeoplasmsAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedMolecular Targeted TherapyPatient SelectionProgression-Free SurvivalRetrospective StudiesSomatostatinAntineoplastic AgentsSomatostatincytotoxic agentmolecular-targeted agentpancreatic neuroendocrine tumorsomatostatin analogtreatment selection MAP

Identifiers

PMID38677983
PMCPMC11322880
OpenAlexW4395956202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.